Live From Shows
-
CPhI Worldwide
CDMOs to Benefit From Rising BTDs, Orphan Drugs and Fast Track Status
CDMOs to Benefit From Rising BTDs, Orphan Drugs and Fast Track Status
The arrival of patient-centric CDMO’s predicted by CPhI Annual Report.
-
CPhI Worldwide
Stevanato, Duoject Enter Auto-injector Collaboration
Stevanato, Duoject Enter Auto-injector Collaboration
Partnership to promote and manufacture the emergency-use ‘Maverick’ auto-injector.
-
CPhI Worldwide
Thermo Fisher Bolsters China Presence
Thermo Fisher Bolsters China Presence
Opens customer solution center in Shanghai to support pharmaceutical and biopharmaceutical laboratories.
-
CPhI Worldwide
C2 Pharma Expands API Portfolio
C2 Pharma Expands API Portfolio
Adds Digoxin micronized grade, Homatropine Hydrobromide and multiple products under tech transfer and development.
-
CPhI Worldwide
CPhI’s 16th Pharma Awards Winners
CPhI’s 16th Pharma Awards Winners
Dr. Ge Li wins ‘CEO of the Year’ and John Chiminski a ‘Lifetime Achievement’ award.
-
CPhI Worldwide
MilliporeSigma Licenses CRISPR Technology to Evotec
MilliporeSigma Licenses CRISPR Technology to Evotec
Will leverage CRISPR Portfolio to develop precisely engineered assays for potential drug candidates during the drug development cycle
-
CPhI Worldwide
West and SCHOTT Enter Packaging Partnership
West and SCHOTT Enter Packaging Partnership
To combine the SCHOTT iQ Platform with West's Ready Pack System.
-
CPhI Worldwide
IDT Biologika, NIH Mfg. Contract Updated
IDT Biologika, NIH Mfg. Contract Updated
Awarded new task order in the scope of 10-year NIH contract to manufacture vaccines and biologics for infectious diseases.
-
CPhI Worldwide
Parsolex Selects Bosch Packaging Technology for New cGMP Facility
Parsolex Selects Bosch Packaging Technology for New cGMP Facility
New Bosch Packaging machines will contribute to a range of clinical supply manufacturing programs.
-
CPhI Worldwide
Lonza Selects Cryoport as Preferred Partner
Lonza Selects Cryoport as Preferred Partner
Will work to remove the supply chain hurdles faced by developers of Cell & Gene Therapies
-
CPhI Worldwide
Recipharm Invests in Nichepharm Lifesciences
Recipharm Invests in Nichepharm Lifesciences
Partnership aims to create production capacity in India for a range of sterile dosage forms
-
CPhI Worldwide
Aptar CSP Launches Xcelerate Development Services
Aptar CSP Launches Xcelerate Development Services
Comprehensive service aims to fast-track active packaging solutions.
-
AAPS PHARMSCI 360
MilliporeSigma Launches New Sucrose Offering
MilliporeSigma Launches New Sucrose Offering
For high risk applications such as injectables and biotherapeutics
-
AAPS PHARMSCI 360
Novel Surfactant Excipient Improves Biologic Stability in Liquid Formulation
Novel Surfactant Excipient Improves Biologic Stability in Liquid Formulation
Joshua Katz of Dupont discusses his work involving new excipients for the biopharmaceutical space
-
AAPS PHARMSCI 360
Cell and Gene Therapy Landscape
Cell and Gene Therapy Landscape
Heather Myler of PPD provides current insight into the growing field of Cell and Gene Therapies
-
AAPS PHARMSCI 360
MilliporeSigma Licenses CRISPR Technology to Evotec
MilliporeSigma Licenses CRISPR Technology to Evotec
Will leverage CRISPR Portfolio to develop precisely engineered assays for potential drug candidates during the drug development cycle
-
AAPS PHARMSCI 360
MilliporeSigma Launches Parteck COAT Excipient
MilliporeSigma Launches Parteck COAT Excipient
Michelle Quinn of MilliporeSigma discusses the company’s new excipient designed for immediate release film coating applications
-
AAPS PHARMSCI 360
-
AAPS PHARMSCI 360
Lonza Selects Cryoport as Preferred Partner
Lonza Selects Cryoport as Preferred Partner
Will work to remove the supply chain hurdles faced by developers of Cell & Gene Therapies
-
AAPS PHARMSCI 360
Vineti, WuXi AppTec Ink Personalized Therapy Management Platform Pact
Vineti, WuXi AppTec Ink Personalized Therapy Management Platform Pact
To combine Vineti's ordering and traceability platform with WuXi's manufacturing facilities to provide end-to-end solution
